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Disclaimer: ACMG standards and guidelines are designed primarily as an educational resource for physicians and other health
care providers to help themprovide qualitymedical genetic services. Adherence to these standards and guidelines does not necessarily
ensure a successful medical outcome. These standards and guidelines should not be considered inclusive of all proper procedures and
tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the
propriety of any specific procedure or test, the geneticist should apply his or her own professional judgment to the specific clinical
circumstances presented by the individual patient or specimen. It may be prudent, however, to document in the patient’s record the
rationale for any significant deviation from these standards and guidelines.
Pompe disease is a rare, progressive, and often fatal muscular
disease. The underlying pathology is a deficiency of the enzyme
acid alpha-glucosidase (GAA) that hydrolyzes lysosomal glyco-
gen. Pompe disease is a single diseasewhichmanifests as a clinical
spectrum that varies with respect to age at onset, rate of disease
progression, and extent of organ involvement. The advent of en-
zyme replacement therapy for this conditionwill necessitate early
diagnosis. This guideline for the management of Pompe disease
was developed as an educational resource for health care provid-
ers to facilitate the prompt and accurate diagnosis and treatment
of patients. An international groupof experts in various aspects of
Pompe diseasemet to review the evidence base from the scientific
literature and their expert opinions. Consensus was developed in
each area of diagnosis, treatment and management in the devel-
opment of this guideline. Thismanagement guideline specifically
addresses evaluation and diagnosis acrossmultiple organ systems
(cardiology, pulmonary, gastrointestinal/nutrition,musculoskel-
etal, neurological) involved in both infantile and late-onset
Pompe disease. Conditions to consider in a differential diagnosis
stemming frompresenting features anddiagnostic algorithms are
provided. Aspects of functional assessment, rehabilitation, nutri-
tional management, emerging therapeutics, care coordination,
nursing, genetic counseling, prenatal diagnosis and screening also
are addressed. A guideline thatwill facilitate the appropriate diag-
nosis, treatment andmanagement of patientswithPompedisease
was developed. It will raise awareness of this condition and the
presentation of patients across the disease spectrum in order to
expedite their diagnosis so they can take advantage of emerging
therapeutics such as enzyme replacement therapy (ERT).
GENERAL/BACKGROUND
Pompe disease, also referred to as acid maltase deficiency
(AMD) or glycogen storage disease type II (GSDII), is an au-
tosomal recessive disorder caused by a deficiency of the lyso-
somal enzyme acid--glucosidase (GAA).1 It was the first rec-
ognized lysosomal storage disease and is the only glycogen
storage disease that is also a lysosomal storage disease. In
Pompe disease, lysosomal glycogen accumulates in many tis-
sues with skeletal, cardiac, and smooth muscle most promi-
nently involved.2,3
All patients with Pompe disease share the same general dis-
ease course, namely the steady accumulation of glycogen sub-
strate in target tissues leading to progressive debilitation, organ
failure and/or death; resulting in a spectrumof disease severity.
Severity varies by age of onset, organ involvement including
degree and severity ofmuscular involvement (skeletal, respira-
tory, cardiac), and rate of progression. Due to the presence of
weakness and hypotonia, it has also been classified as a neuro-
muscular disease or metabolic myopathy. Great phenotypic
variability has led to the creation of types based on the age of
onset and degree of organ involvement. These subtypes have
been referred to inconsistently in the literature by various ter-
minologies such as infantile, late-infantile, childhood, juve-
nile, and adult-onset form.Herein, we have considered Pompe
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disease a continuum of disease spectrum varying by age of
onset, organ involvement and degree of myopathy. In an at-
tempt towards establishing a uniform terminology, we broadly
classify Pompe disease as follows:
infantile form that includes
● patients as originally described by JC Pompe, a Dutch
pathologist, in 19324 who exhibit rapidly progressive dis-
ease characterized by prominent cardiomegaly, hepato-
megaly, weakness and hypotonia, and death due to car-
diorespiratory failure in the first year.5,6 This represents
the most severe end of the disease spectrum and is often
referred to as classic infantile Pompe disease.
● patients with the infantile variant form (nonclassic infan-
tile Pompe disease) with slower progression and less se-
vere cardiomyopathy but presenting in the first year of life
as described originally by Hers1 and, more recently, by
Slonim et al.7 and which has also been variably classified
in the literature with the infantile or childhood forms
(discussed below).
late-onset form that includes
● childhood, juvenile, or muscular variant that is a hetero-
geneous group usually presenting later than infancy and
typically not including severe cardiomyopathy.
● adult-onset form characterized by a slowly progressive
myopathy predominantly involving skeletal muscle that
can present as late as the second to sixth decade of life.
However, it is important to recognize that age of onset does
not always delineate subtypes well; occasional so called “juve-
nile-onset” or mild variant cases may present prior to 12
months of age. Thus the clinical presentation must be consid-
ered along with the age of onset when classifying cases.
Incidence data are limited with reports ranging from 1 in
14,000 to 1 in 300,000 depending upon ethnicity or the geo-
graphic area studied.2 The infantile form has an apparent
higher incidence among African-Americans and Chinese2
whereas the late-onset adult formhas a higher incidence in The
Netherlands.8 In the Netherlands, the incidence of the infan-
tile-onset form is 1/183,000. The combined incidence of all
forms of Pompe disease is estimated to be 1:40,000.2,8,9
Until recently, there has been no specific treatment for
Pompe disease, other than supportive care. Alanine, high-pro-
tein diets, branched chain amino acids and -agonists such as
albuterol10–14 have been reported to offer limited benefits in
some individuals. Epinephrine and glucagon, which enhance
cytosolic glycogen breakdown, have also been attempted with
no therapeutic effect.15 Bone marrow transplantation has not
been shown to be useful, though experience is very limited.16
Similarly, heart transplant for which there is even less experi-
ence has not been shown to be useful (personal communica-
tion, James Leonard, 2006).
Natural history
The clinical presentation of Pompe disease ranges from a
rapidly progressive infantile form which is uniformly lethal
to a more slowly progressive late-onset form. In general,
disease severity typically correlates inversely with residual
acid -glucosidase (GAA) activity. Patients with infantile
Pompe disease present in the first few months of life with a
hypertrophic cardiomyopathy, generalized muscle weak-
ness and hypotonia, followed by death from cardiorespira-
tory failure usually by 1 year.1,2 Two recent studies delineate
the natural history of infantile-onset Pompe disease. The
natural history of classic infantile Pompe disease in 20 orig-
inal Dutch cases and 133 cases from the literature has been
reported.17 In this study, the median age at symptom onset
was 1.6 months in both groups; the median age at diagnosis
(and death) was 5.3 (7.7) and 4.5 (6.0) months in the Dutch
cohort and in the literature cases, respectively. In the second
study the natural history of disease progression was deter-
mined from a retrospective chart review on a worldwide
cohort of 168 patients with infantile-onset (classic and non
classic infantile) Pompe disease. In this study, the median
age at symptom onset was 4 months, first ventilator support
occurred at 5.9 months, and death occurred at 8.7 months.
Despite intervention, mortality remained largely un-
changed over the decades.6,18
In both studies, cardiomegaly, cardiomyopathy, hypotonia,
muscle weakness, respiratory distress, respiratory infections,
feeding difficulties, and failure to thrive were reported as fre-
quently presenting signs and symptoms.5,6,18 In summary,
both studies concluded that the natural history of infantile
Pompe disease has changed little since its original description,
though the absence of large, well characterized and unbiased
data sets has been a limitation.
Late-onset Pompe disease can present at any age and is char-
acterized by a lack of severe (typically absence of) cardiac in-
volvement and a less dismal short-term prognosis.2 Symptoms
are related to progressive skeletal muscle dysfunction. Proxi-
mal lower limb and paraspinal trunk muscles are usually af-
fected first, followed by involvement of the diaphragm and
accessorymuscles of respiration. In some cases, diaphragmatic
weaknessmay be evident before any other significant weakness
is noted.19 As the muscle weakness worsens, patients often be-
come wheelchair users and may require assisted ventilation.
Respiratory failure is usually the cause of significant morbidity
and mortality in this form of the disease. The age of death
varies from early childhood to late adulthood, depending on
rate of disease progression, extent of respiratory muscle in-
volvement and other comorbidities.20
PURPOSE
This guideline is intended as an educational resource. It
highlights current practices and therapeutic approaches to the
diagnosis and management of the multiple complications of
Pompe disease, including emerging therapies such as enzyme
replacement therapy and other potential therapies.
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METHODS/PROCESS
Consensus development panel
An international group of experts in the a) clinical and labora-
tory diagnosis, b) treatment and management (cardiac, respira-
tory, gastrointestinal/dietary, musculoskeletal, neurologic, psy-
chosocial, anesthesiologic, generalmedical, and supportive and
rehabilitative); c) clinical trials of enzyme replacement therapy
andd) genetic aspects of Pompediseasewas assembled in order
to review the evidence base and develop management guide-
lines. Following a meeting during which published material
and personal experience were reviewed by the panel, experts in
the various areas reviewed the literature in these areas and
drafted their appropriate guideline sections. Conflict of inter-
est statements were provided by the participants. However, it is
important to appreciate that many experts may have conflicts
when rare disease treatments are tied to orphan drug designa-
tions and their related marketplace protections. All members
of the panel reviewed and approved the final guidelines. Con-
sensus was defined as agreement among all members of the
panel. For the most part, the evidence and resulting recom-
mendations are considered expert opinion since additional
levels of evidence were not available in the literature. Where
available, evidence from clinical trials is used to guide recom-
mendations. Penultimate drafts of these guidelines were
shared with an external review group consisting of Rochelle
Hirschhorn, MD, Gregory Carter, MD, Johan van Hove, MD,
PhD, James Leonard, MD, Jennifer Li, MD, and Yuan-Tsong
Chen, MD, PhD. Their suggestions were considered by the
working group and changes were made as considered appro-
priate by the working group.
Target audience
This guideline is directed at a wide range of providers. Al-
though care is commonly provided by metabolic disease spe-
cialists/biochemical geneticists and neuromuscular experts, it
is important that primary care providers and other specialists
who are often involved in the care of these patients be able to
recognize these patients in order to intervene and provide the
appropriate care.
DIAGNOSTIC CONFIRMATION
Differential diagnosis
Clinical
The diagnosis of Pompe disease often poses a diagnostic
dilemma due to the rarity of the condition and the relatively
nonspecific nature of the phenotypic features that may only in
aggregate lead to suspicion of Pompe disease. The diseases that
are important in the differential diagnosis of infantile and late
onset Pompe disease are shown in Tables 1 and 2 respectively.
Diagnostic algorithms that stem from key presenting features
for infantile-onset and late onset Pompe disease are shown in
Figures 1 and 2, respectively.21 After diagnosis, the interval for
clinical follow-up of Pompe disease patients must be individ-
ualized for the patient, but a general guide of close followup for
infantile Pompe disease patients and every six months for older
and late-onset Pompe disease patients is useful.
Clinical evaluation
Infantile and Late-Onset Pompe Disease
A chest x-ray and electrocardiogram (ECG) are valuable
screening tests in the diagnostic algorithm for infantile Pompe
disease and an echocardiogram is a valuable next step. Chest
x-ray shows massive cardiomegaly. ECG shows a short PR in-
terval as well as very tall QRS complexes. In a series of 19
patients with infantile onset Pompe disease a short PR interval
was noted in 14 cases (75%).22 Caution in interpreting an
ECGwith attention to voltage calibration is advised, sinceQRS
complex voltage may be very high, and a valuable diagnostic
clue may be missed if the operator has turned the gain down.
Age appropriate norms and adjustment for gestational age for
the PR interval should also be used. Late onset cases rarely
display cardiomegaly on a chest x-ray or ECGwhichminimizes
their utility in these patients. In infantile Pompe disease echo-
cardiogram typically reveals a hypertrophic cardiomyopathy
with orwithout left ventricular outflow tract obstruction in the
early stages of the disease. In the late stages of infantile disease,
patients may have impaired cardiac function and a dilated car-
diomyopathy. Among patients presenting with cardiomyopa-
thy, an electromyogram (EMG) can be useful to document
presymptomatic myopathy. Blood tests should include a se-
rum creatine kinase (CK) examination. CK elevation is a sen-
sitive although very nonspecific marker for Pompe disease.
The greatest elevation is usually found in infantile-onset pa-
Table 1
Differential diagnosis of infantile-onset Pompe disease
Differential diagnosis Shared signs and symptoms
Acute Werdnig-Hoffman
disease (Spinal Muscular
Atrophy I)
Hypotonia, progressive proximal
myopathy, absent reflexes
Hypothyroidism Hypotonia, macroglossia
Endocardial fibroelastosis Breathlessness, feeding difficulties,
cardiomegaly, heart failure
Myocarditis Cardiomegaly
Congenital muscular dystrophy Severe hypotonia and muscle weakness
Glycogen storage diseases:
IIIa (Debrancher deficiency/
Cori or Forbes disease and,
IV (Branching enzyme
deficiency/Anderson disease)
Cardiomegaly, myopathy, elevated
creatine kinase (CK)
Mitochondrial/respiratory
chain disorders
Hepatomegaly, muscle weakness,
cardiomegaly, elevated creatine
kinase (CK)
Danon disease Cardiomegaly, cardiomyopathy,
myopathy, vacuolar glycogen
storage
Idiopathic hypertrophic
cardiomyopathy
Biventricular hypertrophy
Peroxisomal disorders Hypotonia, hepatomegaly
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tients (as high as 2000 UI/L). Approximately 95% of late-onset
patients have an elevated CK23; however, some adults with
Pompe diseasemay haveCK levels within the normal reference
range. Serum enzymes such as aspartate aminotransferase
(AST), alanine aminotransferase (ALT), or lactate dehydroge-
nase (LDH) may be elevated and may reflect enzymes released
from muscle.24 There is increasing evidence of the value of a
specific glucose tetrasaccharide in urine [Glc4 (Glc1-6Glc1-
4Glc1-4Glc)] in the evaluation of Pompe disease.25 Like CK,
Glc4 is a sensitive though nonspecific marker for Pompe dis-
ease. It can also be elevated in other glycogen storage diseases
and clinical correlation is needed. As the clinical presentation
in late-onset cases is typically that of a proximal myopathy,
much of the evaluation involves laboratory testing of muscle
(i.e., EMG, nerve conduction studies and/or muscle biopsy for
histology, histochemistry and enzyme assay). Many of the lab-
oratory tests that are useful in the evaluation of suspected in-
fantile onset Pompe disease are also valuable in considering the
late onset form (i.e., CK, AST, ALT, LDH and Glc4). Pulmo-
nary function testing can identify respiratory compromise in
both.
Laboratory testing
Diagnostic Testing
The clinical diagnosis is traditionally confirmed by the vir-
tual absence (infantile-onset) or markedly reduced (late-on-
set) GAA activity in tissues such as cultured fibroblasts from
skin biopsy, muscle biopsy, purified lymphocytes, mononu-
clear cells and lymphoid cell lines. However, historically GAA
enzyme measurement is most reliably performed in cultured
fibroblasts or muscle, due to the possibility of alternate isoen-
zyme activities (e.g.,maltase-glucoamylase as discussed below)
masking disease in white cell assays. Acid alpha glucosidase
(GAA) has an optimumactivity at pH 3.7 to 4.5 and hydrolyzes
alpha 1-4 and alpha 1-6 bonds in glucose polymers. In a typical
assay, GAA activity is measured at an acidic pH (3.7 to 4.5) and
comparedwith the activity of neutral glucosidase at pH7.0, using
maltose and glycogen or the maltose fluorescent synthetic ana-
logue, 4-methylumbelliferyl--D-glucoside (4-MUG) as sub-
strates.
Measurement of GAA activity in skin fibroblasts is the cur-
rent gold standard. Cultured fibroblasts are obtained from a
skin biopsy which is then grown to confluency prior to the
enzyme assay. This can take up to 4–6 weeks, and can thus
significantly delay the diagnosis. Muscle tissue biopsy, al-
thoughmore invasive, allowsmuscle acid--glucosidase activ-
ity and glycogen content to be assayed directly and rapidly. It
can also be used for histological studies to assess the location
and amount of glycogen accumulation in the tissue. Great care
in handling is required so as not to wash out glycogen and alter
cell and tissue pathology. In late-onset Pompe disease, the site
of muscle biopsy can impact results due to the variability of
glycogen accumulation both between different muscles and
between the muscle fiber type within a muscle. Furthermore,
there is anesthesia risk (see section below) in infantile Pompe
disease if an open biopsy is done.26 This risk should be carefully
considered, particularly if the patient is already shown to have
severe cardiomyopathy and skeletal myopathy.
Muscle biopsy in Pompe disease shows the presence of vacu-
oles that stain positively for glycogen. In advanced stages of the
disease, glycogen accumulation is seen both in the lysosomes
and dispersed in the cytosol. Quantitatively, muscle glycogen
content is elevated up to tenfold above normal in infantile
Pompe disease and to a lesser extent in late onset patients.
In thepast, leukocytes isolated fromwholebloodhavenotbeen
a reliable tissue for themeasure ofGAAactivity owing to interfer-
ing maltases.27 The most significant interference has been rec-
ognized as the maltase-glucoamylase (MGA) activity found in
polymorphonuclear leukocytes. An improved assay has been de-
scribed that uses an isolated lymphocyte population and acarbose
as an inhibitor of MGA (personal communication, Rhona Jack,
PhD), though it may require further validation.
New methods have been developed that assay GAA activity in
dried blood spot (DBS) extracts. Isolation of GAA fromDBS ex-
tracts by immunocapture28 or competitive inhibition ofMGAac-
tivity using maltose29,30,32 or acarbose31,32 have been used to re-
move the interfering MGA activity. DBS can be conveniently
Table 2
Differential Diagnosis of Late-Onset Pompe Disease
Differential diagnoses Shared signs and symptoms
Limb girdle muscular dystrophy
(LGMD)
Progressive muscle weakness in the
pelvis, legs and shoulders
Becker muscular dystrophy
(BMD)
Progressive proximal muscle
weakness, respiratory
impairment, difficulty walking,
elevated creatine kinase (CK)
Scapuloperoneal syndromes Progressive muscle weakness
behind the knees and around
the shoulder blades
Rigid spine syndrome Spinal rigidity, lower back pain
Myasthenia gravis Generalized muscle weakness
Spinal muscular atrophy Asymmetrical muscle weakness,
atrophy of voluntary muscles
Polymyositis Unexplained muscle weakness
Glycogen storage diseases: IIIa
(Debrancher deficiency/Cori
or Forbes disease, IV
(Branching enzyme deficiency/
Anderson disease), V (Muscle
phosphorylase deficiency/
McCardle disease), and VII
(Muscle phosphofructokinase
deficiency/Tauri disease)
Hypotonia, hepatomegaly, muscle
weakness, elevated creatine
kinase (CK)
Danon disease Hyertrophic cardiomyopathy,
skeletal muscle myopathy,
vacuolar glycogen storage
Rheumatoid arthritis Stiffness/pain upon exertion
Mitochondrial myopathies Hyptonia, hyporeflexia,
hepatomegaly. Some forms with
hypertrophic cardiomyopathy,
muscle weakness, elevated
creatine kinase (CK)
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collected by the heel- or finger-stick method and shipped from
locations remote from the analytical center.32 These novel DBS
methods are not only suitable for newborn screening of Pompe
disease, but also offer a rapid, noninvasive first tier diagnostic test
for ruling out Pompe disease. Blood can be directly spotted onto
filterpaperand, in situationswhereaccess to filters isnotavailable,
whole blood can be sent to a diagnostic laboratory. Such tests in
clinical investigationarebest accessedby specialistswhoare aware
of their limitations and theymay savevaluable time inpatient care
and treatment.
Elevation ofGlc4 in urine has been identified in patientswith
Pompe disease. Diagnostically, it has close to 100% sensitivity
in identifying patients with infantile Pompe disease.25,33 As a
biomarker, it has been shown to correlate well with the clinical
response to ERT.33,34 Analysis of urinary Glc4 is recommended
as a noninvasive ancillary diagnostic test for Pompe disease.
This method has also been validated for dried urine on filter
paper, which facilitates collection and shipment from locations
remote from an analytical center. When combined with the
aforementionedGAAenzyme assay inDBS, the diagnostic sen-
sitivity should be close to 100% for infantile Pompe disease. It
is equally important to note that negative results from both
tests would almost certainly rule out a diagnosis of infantile
Pompe disease and eliminate the need for more invasive or
time-consuming procedures such as skin or muscle biopsies.
These assays are done in specialized laboratories only and are
currently notwidely available outside of clinical investigational
studies.
In general, GAA enzyme activities of1% of normal controls
are seen in the infantile form of Pompe disease. In the late onset
forms, activities from 2 to 40% of normal controls are seen and
can vary across tissues with muscle tissue showing wider ranges
due to the variability in protein content inmuscle as compared to
fibroblasts. Clinical correlation andmolecular diagnosis are often
needed however, as there are reports of late onset patients with
1%GAA activity in skin fibroblasts. Laboratory testing to con-
firm a diagnosis of Pompe disease thus includes several blood
tests, some of which may preclude the need for more invasive
testing. A diagnostic algorithm including testing to consider the
Fig. 1. Diagnostic algorithm for infantile onset Pompe disease.
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infantile form is presented in Figure 1 and for the late onset form
in Figure 2.
Mutation Analysis:While enzyme activity analysis remains the
diagnostic test of choice for individuals with Pompe disease, mu-
tation testing has important uses. It is particularly useful in the
identification of carriers when a familial mutation is known.
There are also some common mutations with useful genotype-
phenotype correlations, though many are less specific or are of
such infrequent occurrence as to be less useful in this context.35–38
Due to the potential overlap of residual GAA enzyme activity in
late-onset Pompe with heterozygotes, molecular analysis of the
GAA gene may be required to confirm the diagnosis. This is in-
creasingly important with the advent of ERT and other therapies
indevelopment forPompedisease.More than100mutations and
numerous variants in the GAA gene have been identified and are
catalogued by the Erasmus University Medical Center in Rotter-
dam, Netherlands (http://www.eur.nl/FGG/CH1/Pompe/). The
mutations are spread across the gene though mis-sense
mutations in exon 14 may be over represented. Among the
recurrent mutations in the infantile-onset cases is a single
base pair deletion, 525T, that is seen in 9% of U.S. cases.37
This same mutation accounts for 34% of Dutch cases.38 The
exon 18 deletion mutation is seen in infantile-onset cases
and accounts for about 25% of Dutch and Canadian cases
but only about 5% of U.S. cases.37,38 The leaky IVS1(-13T-
G) splice-site mutation accounts for about 50% of late-
onset cases. There are some populations in which particular
mutations are more common due to founder effects while
allelic heterogeneity can be significant in admixed popula-
tions as exist in the U.S. The R854X mutation is found in
many African American and African cases; D645E is seen in
many Chinese infantile cases; the 2741AG-CAGG inser-
tion is seen in Turkish cases; and the G925A mutation is
seen in many European cases.
Fig. 2. Diagnostic algorithm for late onset ( 1 year) Pompe disease.
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DIAGNOSTIC TEST RECOMMENDATIONS
● Detailed diagnostic algorithms are provided in Figures 1 and 2 for both infantile and late-onset Pompe disease.
● Currently, acid -glucosidase (GAA) assay performed on skin fibroblasts (preferred tissue) or muscle biopsy, by experienced
laboratories is the diagnostic “gold standard” as it can render a definitive diagnosis of Pompe disease, when combined with
clinical and laboratory data (muscle histology when available).
● GAA assay in blood collected on filter paper (dried blood spots) is poised to become a reliable, relatively noninvasive and specific
assay with the further advantage of a rapid turn around time.
● Dried blood spot/lymphocyte assay and peripheral blood mononuclear cell assay, when done with appropriate inhibitors to
inhibit the interfering MGA activity, perhaps in combination with the urine glucose tetrasaccharides (Glc4) assay, are useful
adjuncts in the diagnostic work up of Pompe disease whose roles are evolving.
● Laboratory testing to help in the initial evaluation of a patient suspected of having Pompe disease, regardless of the type,
should include serum creatine kinase (CK), AST, ALT, LDH, and urine for Glc4 may also be useful.
● Analysis of leukocyte vacuoles for glycogen by PAS staining is an inexpensive, quick and reliable test for Pompe disease used
in some centers.
● Molecular analysis may be helpful in selected cases. Determination of the common late-onset splice site mutation is useful in
Caucasians.
OVERVIEW OF MANAGEMENT
Pompe disease is a multi-system disorder and is best man-
aged by a multidisciplinary team led by a physician with expe-
rience managing this disorder. Teammembers should include
a metabolic disease specialist/biochemical geneticist in addi-
tion to the specialists dictated by the disease manifestations,
which might include a cardiologist, pulmonologist, neurolo-
gist, neuromuscular specialist, intensivist, orthopedist, respi-
ratory therapist, physical therapist, occupational therapist,
otolaryngologist, speech therapist, audiologist, genetic coun-
selor, and a metabolic dietitian. All specialists involved in the
care of an individual with Pompe should have an understand-
ing of the disease, its broad and protean manifestations, and
challenges, including the psychological and emotional impact
of this devastating disease on patients and families. There
should be a team member with experience in Pompe disease
(e.g., the metabolic specialist) who is able to coordinate the
patient’s care.
CARDIOLOGY
The common cardiac issues occurring in Pompe disease in-
clude cardiomyopathy, heart failure and arrhythmia. There is
also a component of cardiac dysfunction which contributes to
respiratory failure from a hemodynamic standpoint and from
the impact of cardiac size on lung capacity.
Cardiomyopathy
In infantile Pompe disease, the effects of glycogen accu-
mulation are very pronounced in the heart. Lysosomal gly-
cogen accumulation results in a significant amount of car-
diac hypertrophy (between 2 and 10 or higher z-score
for LV mass) that may begin in utero and that is significant
even at 4–8 weeks of age (personal communication, Car-
olyn Spencer, MD; Jami Levine, MD; Barry Byrne, MD,
PhD, 2005). The cardiac response to glycogen accumulation
can result in hypertrophic or hypertrophic and dilated car-
diomyopathy. Beyond infancy there is variable involvement
of the heart in Pompe disease and a spectrum of disease
among children with partial enzyme activity ranging from
unaffected to moderate cardiac hypertrophy and cardiac
dysfunction (personal communication, Carolyn Spencer,
MD; Jami Levine, MD; Barry Byrne, MD PhD, 2005). In
patients with late onset Pompe disease there is generally no
clinically identifiable heart disease. However, there are no
published data of systolic and diastolic function in this
group of patients. There are case reports of late-onset
Pompe patients with cardiac disease which was thought to
be influenced by the glycogen storage39 yet this is the excep-
tion rather than the rule.
Electrophysiological findings and potential for arrhythmia
Interference with specialized conducting tissues produces
a shortening of the atrio-ventricular (P-R) interval on the
ECG.39 The mechanism of accelerated atrioventricular con-
duction in Pompe disease may be related to the insulator
effect of glycogen in conduction tissue40,41 however glyco-
gen accumulation can also result in a short PR in association
with other models of glycogen storage.42 True Wolf-Parkin-
son-White syndrome has been reported to occur in Pompe
disease43 as well, though a coincidental occurrence can not
be ruled out. These conduction abnormalities, in conjunc-
tion with the hypertrophic cardiomyopathy, place these pa-
tients at high risk of tachyarrhythmia and sudden death,
especially in situations of stress such as infection, fever, de-
hydration and anesthesia.26,40 Twenty-four hour ambula-
tory ECG (Holter monitoring) is thus useful in the manage-
ment of Pompe disease patients.44
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Routine evaluation in Pompe
The assessment of cardiac function by echocardiography is an
essential part of the ongoingmanagement of Pompepatients. Ini-
tial findings of increased wall thickness and left venticular (LV)
mass need to be evaluated on a regular basis by a standardized
approach since establishing the stage of the cardiomyopathy is
useful indetermining treatment.This also canhelpwith following
disease progression and response to intervention. The LV mass
evaluated by two dimensional measurements using the length-
area relationship has provided the most reliable assessment. The
absolute mass value (not indexed for BSA) is compared to a nor-
mal control population to yield a z-score which is an indicator of
how far the patient exceeds themean left ventricularmass in nor-
mal subjects. Functionalmeasures including2-Dejection fraction
(EF) and the myocardial performance index are helpful in longi-
tudinal follow-up.
Management
Cardiomyopathy in patients with Pompe disease should be
treated cautiously and preferably by a pediatric cardiologist
who has experience with the disease. Care needs to be individ-
ualized and based on the stage of disease, since inappropriate
use of the standard drugs used to treat cardiomyopathy may
worsen an already compromised heart. Infants who present
with Pompedisease in the earlier phases of the disease generally
present with severe ventricular hypertrophy with or without
left ventricular outflow tract obstruction and normal or even
hyperdynamic left ventricular EF. In the presence of LV out-
flow tract obstruction, the use of digoxin, other inotropes, di-
uretics, and afterload reducing agents such as ACE-inhibitors
may exacerbate the left ventricular outflow tract obstruction.
These agents, however, are generally used in the later phases of
the disease in the face of ventricular dysfunction.3 Several an-
ecdotal unreported cases of sudden death associated with the
use of beta blockers in Pompe patients have suggested that this
class of drugs should be used judiciously. Furthermore, in any
case of cardiac hypertrophy there is potential for arrhythmia
whichmay be due to underlying subendocardial ischemia from
inadequate coronary perfusion of a massively hypertrophied
ventricle. Therefore, special care must be taken in Pompe dis-
ease patients to avoid hypotension in diagnostic procedures
requiring anesthesia (see below) or when there is volume
depletion.26 Reduction in cardiacmass is observed during ERT
and reverse remodeling does occur to varying degrees leading
to changes in cardiac function asmeasured by EF. A transient fall
inEFhasbeennoted in the first 12–24weeksof therapyand there-
foremeasurementofmyocardialperformance index isuseful.De-
velopment of ventricular ectopy on ERT has been noted, under-
scoring the need for monitoring with twenty-four hour
ambulatory ECG’s at regular intervals.44
CARDIOLOGY RECOMMENDATIONS
● Chest x-ray at regular intervals (see pulmonary recom-
mendations).
● Obtain an initial echocardiogram to evaluate the extent
of cardiomyopathy, repeat at regular intervals.
● Medical management may be useful based on stage of
cardiomyopathy.
● Avoid drastic changes in fluid status, either through de-
hydration or fluid overload.
● Obtain a twenty-four hour ambulatory ECG at baseline
and regular intervals as patients are at risk for life-threat-
ening arrhythmias.
● Monitor for arrhythmias, including in patients on ERT.
PULMONARY
As Pompe disease progresses, themuscles weaken leading to
low lung volumes, an impaired cough, blood gas abnormali-
ties, and sleep-disordered breathing. These changes are similar
to those seen in any patient with an underlying neuromuscular
weakness, such as Duchenne muscular dystrophy and spinal
muscle atrophy.45 Patients with Pompe disease are also at an
increased risk for aspiration pneumonia (see GI section be-
low). While disease progression in patients with the infantile
form is rapid,5,6,17 patients with late onset Pompe disease have
a more gradual onset of similar, but initially less severe, respi-
ratory compromise.
Progressive loss of pulmonary function
Approximately 60% of patients with late-onset Pompe dis-
ease have a mild reduction in vital capacity (80% predicted)
and 30–40% have moderate reduction (60% predicted).35,46,47
Although the pattern of muscle weakness is variable, a rough
correlation has been observed betweenmeasures of pulmonary
function and proximal muscle weakness, particularly in the
lower extremities.47 Diaphragmatic involvement can be an
early and prominent finding in Pompe disease and respiratory
failure often develops while patients are still ambulatory; it
may even be the initial clinical manifestation of the dis-
ease.35,46,48–50 Diaphragm weakness may be characterized by a
decrease in the vital capacity (VC) while the patient is in the
supine versus prone position (a 10% decrease in VC indicates
mild diaphragmatic weakness; a 30% decrease indicating se-
vere weakness).50 Diaphragmatic dysfunction and VC are pre-
dictive of the development of chronic sleep hypoventilation
and respiratory failure. Objective assessment of pulmonary
function in infants is technically difficult, thus complete pul-
monary evaluation requires assessment of clinical factors such
as daytime energy-level and degree of fatigability (i.e., the abil-
ity to feed without developing increased work of breathing).
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Impaired cough due to abdominal muscle weakness
Impaired cough results in retained secretions and an inabil-
ity to clear both the normal volume of pulmonary secretions as
well as those associated with acute infections, thereby predis-
posing the patient to developing atelectasis and pneumonia.
Patients with infantile onset disease are especially vulnerable to
left lower lobe atelectasis secondary to the enlarged heart com-
pressing the left main stem bronchus. In patients with late
onset Pompe disease measurement of the maximal expiratory
pressure (MEP), maximal inspiratory pressure (MIP), expira-
tory reserve volume, and peak cough flow provide objective
measurements of muscle strength while for those with early
onset disease,measurement of theNegative Inspiratory Forced
Maneuver (NIFM) or MIP may be used to obtain this infor-
mation.
Progressive respiratory insufficiency
Chronic CO2 retention (elevated arterial pCO2 and serum
bicarbonate concentration) and hypoxemia (decreased arterial
pO2 and oxygen saturation) are seen as muscle weakness
progresses, usually developing first while asleep, and then later
when awake. In late onset patients, respiratory insufficiency
may only be minimally perceived, especially when exercise ca-
pacity is limited secondary to skeletal muscle weakness.
Sleep disordered breathing
This is often present in patientswith Pompe diseasewith respi-
ratory muscle weakness because of the mechanical disadvantage
of the supinepositionand theeffectof sleeponrespiratory control
mechanisms. Decrease in upper airway tone, especially during
REM sleep, may further compromise ventilation. Nocturnal hy-
poventilation commonly precedes daytime respiratory failure. In
patients with late onset disease, this may occur while the upright
vital capacity is only moderately abnormal due to the dispropor-
tionate diaphragmatic involvement.47 Pompe patients may also
have an impaired ability to compensate for any obstructive sleep
apnea that may be present51–53 leading to worsened hypercapnia
and hypoxemia.41,54 Progression to cor pulmonale and cardiore-
spiratory failure is possible. In infantile Pompe disease, sleep
disordered breathing may develop before the parents report
symptoms.55
Routine evaluation of respiratory function
Assessment of the patient’s respiratory status should be
done at each visit, with emphasis on the patient’s cough, the
presence ofwheezing or shortness of breath, exercise tolerance,
energy level, degree of fatigueability, and in infants, their abil-
ity to feed. Physical examination should focus on the respira-
tory rate, the use of accessory muscles of respiration, adequacy
of air exchange, presence or absence of adventitial breath
sounds, and quality of the patient’s cough. In late onset cases,
pulmonary function should include spirometric measurement
of VC, forced expiratory volume in 1 second (FEV1), MIP and
MEP. Diaphragm weakness can be further evaluated by mea-
surement of the supine vital capacity. For infantile onset dis-
ease, spirometry is not an option and infant pulmonary func-
tion testing may require sedation, which is not advisable.
When available, measurement of crying vital capacity (CVC)
can give reproduciblemeasurements of the infant’s vital capac-
ity. Negative inspiratory flowmeasurement (NIFM), a param-
eter similar to the MIP, gives a measurement of inspiratory
muscle strength.56 Gas exchange should be evaluated in all pa-
tients to assess for the development of respiratory failure. Pulse
oximetry and capnography should routinely be performed. If
normal, arterial blood gas analysis is usually not necessary. If
capnography is not available, a venous bicarbonate and/or
pCO2 or capillary blood pCO2 should be obtained to assess
for alveolar hypoventilation. Chest radiographs may be useful
for determining the presence of atelectasis and help determine
where chest physical therapy needs to be directed. Radiographs
should be obtained upon diagnosis and if there is clinical de-
terioration (a significant change in auscultation or worsening
of O2 saturation and/or ventilation parameters).
Routine evaluation of sleep respiratory function
All patients with Pompe disease should have a detailed sleep
history obtained at diagnosis and at follow up appointments.
The American Academy of Sleep Medicine recommends full
polysomnography for all sleep evaluations.57 Alternative stud-
ies (such as pulse oximetry and/or capnography) are insuffi-
cient to assess for sleep disordered breathing, though theymay
be used to assess for nocturnal hypoxia or hypoventilation,
respectively.57 Oximetry alone is not a sufficient screeningmo-
dality for the assessment of sleep disordered breathing.57–59
Symptoms suggesting sleep disordered breathing include snor-
ing, apneas, gasping respirations, restless sleep, irritability, or
excessive daytime somnolence (the latter in late onset pa-
tients). Detailed examination of the nasopharynx and oro-
pharynx should assess for the presence of (possible) obstruc-
tion. Patients should be objectively assessed for obstructive
sleep apnea or hypoventilation at diagnosis with polysomnog-
raphy, regardless of symptoms history. Treatment of respira-
tory insufficiency and obstructive sleep apnea should be fol-
lowed with some type of monitoring so as to document its
effectiveness. Follow up sleep studies should be performed
when clinically indicated.57
Management
Addressing impaired secretion clearance due to weakened
cough is critical tomaintaining optimal functional status. Both
manual andmechanical techniques used in treating other neu-
romuscular disorders should be used to assist cough and pre-
serve pulmonary function.45,55 Liberal use of bronchodilators
should be used in conjunction with these airway clearance
techniques and assisted coughing maneuvers (i.e., The Cough
Assist In-Exsufflator)60 to maximize the patient’s pulmonary
toilet care. Inspiratory muscle training may also be important.45
Bronchodilators and steroids (both inhaled and/or oral) can be
useful when an asthmatic process is present. If there is under-
lying cardiomyopathy, the use of selective beta agonists (e.g.,
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levalbuterol) may be recommended. All pulmonary infections
should be aggressively treated.
Supplemental O2 (either nocturnal or continuous) can be
used to treat hypoxia, provided that hypoventilation is not
present. If hypoxia occurs only during sleep, management is
controversial. While most practitioners give nocturnal O2 for
the hypoxia, it seems reasonable that patients with obstructive
sleep apnea be first managed with support of the upper airway
(nasal C-PAP), and that those with nocturnal hypoventilation
bemanaged with nocturnal noninvasive positive pressure ven-
tilation (Bi-level ventilation) before O2 is added. This ap-
proach has been shown to be effective and well tolerated in
infants with Pompe disease.55 If hypoventilation is present
while both awake and asleep, consideration should be given to
using continuous noninvasive positive pressure ventilation or
even tracheostomy tube placement with mechanical ventila-
tion.
PULMONARY RECOMMENDATIONS
● Clinical assessment of respiratory status, both asleep and
awake, should be performed at each medical visit.
● When feasible, assessment of pulmonary function and
gas exchange should be performed at diagnosis, annu-
ally, and at every visit or with changes in patients’ clini-
cal condition.
● Chest radiographs should be obtained upon diagnosis
and when clinically indicated.
● Polysomnography should be performed upon diagnosis
and when clinically indicated in infantile and late onset
Pompe disease.
● Maximizing clearance of airway secretions should rou-
tinely be performed.
● Assessment of respiratory function during sleep needs to
be made whenever the patient complains of daytime
sleepiness, unexplained fatigue or has observed apneas
during sleep, or when vital capacity falls below 40-50%
predicted.
● Supplemental oxygen and/or noninvasive positive pres-
sure ventilation should be prescribed based on underly-
ing ventilatory abnormalities such as hypoxemia, ob-
structive sleep apnea, and hypoventilation. Treatment
modality should be based on a firm diagnosis of the type
of respiratory events seen during sleep.
● All pulmonary infections should be aggressively
managed.
GASTROINTESTINAL/NUTRITION
Patients with Pompe disease have feeding and swallowing
difficulties and often fail to thrive. In infantile Pompe disease,
contributing factors include facial hypotonia, macroglossia
and/or tongue weakness, poor oral range of motion with ex-
tremely limited tongue elevation and decreased ability to
achieve tongue cupping and lip seal for sucking. These patients
have difficulty with saliva management and are less vigilant
with regard to swallowing causing pooling of secretions and
drooling. Vocal quality is often noted to be “wet” indicating
pooling of secretions at the level of the vocal cords, correlating
with increasing respiratory complications which could be sec-
ondary to aspiration events. In patients with late onset Pompe
disease, fatigue of jaw muscles with difficulty swallowing a bo-
lus and chewing food is often a first complaint and this often
results in an inadequate intake of total calories, vitamins, and
minerals leading to endogenous muscle protein breakdown.
Swallowing dysfunction can be diagnosed in patients with
Pompe disease by a videofluoroscopic swallowing assessment
which identifies impairments in the different phases of swal-
lowing and should be done at baseline in all newly diagnosed
cases. In the oral phase of the swallow study, deficits include
decreased sucking strength, oral dysmotility, and/or delayed
initiation of the swallow reflex to the level of the valleculae or
pyriform sinus. Mild to moderate residue after completion of
the swallow is noted in the pharyngeal phase. A 4 point scale
can be used to assess the degree of dysfunction in the oral and
pharyngeal phase of swallow.61
Patients with Pompe disease are at increased risk for aspira-
tion. By using a scale such as the Penetration/Aspiration Scale
the risk for laryngeal penetration and/or presence of aspiration
can be assessed.62 Penetration of liquid into the laryngeal ves-
tibule and aspiration has been documented as early as age 4
months in babies with Pompe disease (personal communica-
tion, Priya Kishnani, MD 2006). Management by a feeding
team that includes a speech pathologist and a dietician (pref-
erably one experienced in metabolic diseases) is of paramount
importance in developing and monitoring a feeding plan. If
problems are noted in the swallow study, modification of di-
etary texture with commercial thickeners or cereals may be
utilized to provide a safe feeding regimen. If, however, the risk
for aspiration is high, oral feeds may need to be discontinued
and the patient gavage fed. Evaluation for gastroesophageal
(GE) reflux should be undertaken when indicated to deter-
mine site of gavage feeding. In instances when there is signifi-
cant GE reflux, nasoduodenal or gastro-jejunal feeding is rec-
ommended rather than nasogastric feeding to minimize the
risk of aspiration. One should avoid long surgical procedures,
such as a Nissen fundoplication because of high anesthesia risk
and low success rate in patients with an underlying myopathy.
In some instances a combination of oral and tube feeding to
allow for adequate intake of calories, and to allow for normal
oral sensory development may be recommended.
Oral stimulation and non-nutritive sucking for nonoral
feeders should be provided to maintain normal oral sensory
development and to develop emerging oral skills. Modified
dietary textures should be re-evaluated on a regular basis to
maintain safety in light of a changing disease process. Improve-
ments in swallowing dysfunction have been noted in some in-
fantile-onset patients receiving ERT and patients have been
able to resume oral feeding. Growth parameters such as height,
weight and head circumference should be followed closely.
Changing the texture and on occasion pureeing food has also
been found to be extremely useful in the late onset cases.
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For patients with late-onset Pompe disease, the goal is in-
tended to manage 1) the increasing accumulation of glycogen
and 2) the increase in amino acid utilization.7,11 Slonim et
al.63,64 have observed that a high protein-low carbohydrate diet
plus aerobic exercise, can be beneficial to some of these pa-
tients (see cautions on limits of exercise in the Musculoskele-
tal/Functional/Rehabilitation section). The rationale to this
form of therapy is an attempt to decrease glycogen deposition,
increase muscle fatty acid utilization, and at the same time
compensate for the increased amino acid oxidation that
has been shown to occur in Pompe disease.63 A study by
Bodamer,13 however, failed to demonstrate improvement in
their late-onset Pompe disease patients treatedwith a high pro-
tein diet and alanine supplementation. A high protein dietmay
be a good adjunct to ERT but randomized controlled studies
are needed.Overall,maintaining goodnutritionwith attention
to macro and micronutrients is important in the management
of all patients with Pompe disease.
GASTROINTESTINAL/NUTRITION RECOMMENDATIONS
● Obtain videofluoroscopic swallowing assessment and
evaluation for GE reflux to guide management of feed-
ing (oral/gavage feeding) at baseline and as clinically in-
dicated.
● Provide oral stimulation and non-nutritive sucking for
infants who are nonoral feeders.
● Monitor growth parameters carefully.
● Provide adequatenutrition (highprotein consistingof 20–
25% protein) with attention to vitamins andminerals.
● Encourage appropriate exercise in consultation with a
physical therapist with experience in Pompe disease.
MUSCULOSKELETAL/FUNCTIONAL/REHABILITATION
Musculoskeletal system and function
Musculoskeletal involvement in Pompe disease is character-
ized by progressive weakness that leads to decreased motor
function, altered postural tendencies and positioning, and the
use of compensatory patterns of movement. Secondary mus-
culoskeletal impairments such as contracture, deformity, and
osteoporosis can occur and further compromise function.
Gross and fine motor function may be limited by weakness,
decreased endurance, secondary musculoskeletal impairment,
and cardiorespiratory impairment (see Case &Kishnani article
in this issue for details).65 Communication and interaction
may be compromised by oral-motor weakness that impairs
speech, articulation, and phonation and by decreased respira-
tory function for support of phonation and sound production.
Pathology of muscle weakness
Myopathy results from glycogen accumulation in muscle,
leading to compromised muscle function and progressive
weakness. Muscles may feel firm or hypertrophic despite
weakness.2,3 Distribution and extent of weakness vary depend-
ing on severity of disease with weakness usually greater proxi-
mally than distally and greater in lower extremities than in
upper extremities.Weakness is usually symmetrical but imbal-
anced across joints. Weakness that affects pulmonary and re-
spiratory function is covered in the pulmonary/respiratory
section.Weakness that affects oralmotor function in feeding is
covered in the gastrointestinal/nutrition section.
Pathokinesiology of muscle function and secondary
musculoskeletal impairment
Profound generalized weakness in infantile onset Pompe
disease can limit all movement or most antigravity movement.
Imbalancedweakness leads to alterations in posture andmove-
ment used to mechanically lock joints and compensate for
weakness.66Momentum is used tomaximize kinematic advan-
tage. Although compensations are effective in maximizing
function initially, persistent use of compensation over time can
lead to biomechanical disadvantage, contracture, and defor-
mity leading to increasing weakness and disability.67,68 With
severe, early weakness, the unopposed influence of gravity has
the most profound effect on positioning and the development
of contracture and deformity. With mild to moderate weak-
ness, imbalanced weakness and compensatory movement pat-
terns and postures have an increased role in the development
of contracture and deformity.
Osteopenia and osteoporosis
Osteopenia and osteoporosis have recently been recognized
as complications of Pompe disease. Thoracic vertebral fracture
was reported in the case study of an adult patient with late
onset disease who had osteopenia, hypomagnesemia, hypocal-
cemia, and hypocalciuria.69 Femoral and thoracic vertebral
fractures have been identified in patients with infantile onset
Pompe disease.70 Osteopenia has been seen in patients with
Pompe disease as young as 4 months of age, which could be
attributed to chronic immobilization and weakness, but os-
teopenia has also been identified in patients with Pompe dis-
ease with goodmotor strength and nutrition71 and needs to be
further studied. The pathophysiologicmechanisms of osteope-
nia/osteoporosis in Pompe disease are not yet well understood
so are managed generically.71,72
Routine evaluation in Pompe (see Appendix A):
Multidisciplinary evaluation should include assessment
within each category of the World Health Organization
(WHO) International Classification of Functioning, Disabil-
ity, and Health (ICF).73 Specific assessments are outlined in
Appendix A.
Rehabilitation management of Pompe disease
Rehabilitationmanagement of Pompe disease should be com-
prehensive and preventative, based on an understanding of the
pathokinesiology of disease progression and on individual
assessment.74 It should optimize and preservemotor and physio-
logical function, prevent or minimize secondary complications,
promote andmaintain themaximum level of function, andmax-
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imize the benefits of ERT and other therapies when they become
available. Rehabilitation services should include physical therapy,
occupational therapy, speech therapy, respiratory therapy, ortho-
pedics, early intervention/educational/vocational rehabilitation
and independent living services, and the use of adaptive equip-
ment, assistive technology, and orthotic intervention where indi-
cated. Rehabilitation related to respiratory and pulmonary issues
are discussedwithin those sections of this guideline.Management
of feeding as relates to oral motor function is addressed in the
gastrointestinal/nutrition section.
Strengthening
Guidelines for muscle strengthening are not established for
individuals with Pompe disease. Studies of the effect of
strengthening in individuals with Pompe have been few, with
small numbers and recommend the use of submaximal and
aerobic exercise.63,64,75 Caution regarding exercise in the pres-
ence of myopathy and cardiorespiratory compromise is im-
portant. Excessively strenuous exercise is believed to be detri-
mental inmost diseases characterized bymuscle deterioration,
as it may increase degeneration, and should be avoided. In
Pompe, additional potential, theoretical concern exists that ex-
cessive contraction could increase leakage of glycogen from
lysosomes or cause lysosomal rupture.76
Medical stability should be established prior to initiation of
therapeutic activity, with appropriate subsequent monitoring
of cardiopulmonary response to activity level, exercise, and
position (especially supine). Precautions regarding strength-
ening of fragile muscles should be followed using guidelines
from other degenerative muscle diseases,77,78 including an em-
phasis on the use of submaximal and aerobic exercise; avoid-
ance of excessive resistive and eccentric exercise; use of func-
tional activities for exercise; and avoidance of overwork
weakness, disuse atrophy, and excessive fatigue. Although ex-
cessively strenuous exercise should be avoided, gentle sub-
maximal exercise is believed to be important to allow practice
of new motor skills, especially in children; to allow gentle
strengthening within physiological limits; to avoid additional
disuse atrophy, especially in muscles not be used spontane-
ously because of biomechanical compromise and relative
weakness compared to other muscles; and to avoid secondary
cardiopulmonary compromise and deconditioning from inac-
tivity. In addition, there is evidence that submaximal exercise
may stimulate the degradation of some of the glycogen that
accumulates in the cytosol.75 Intervention for enhancing mus-
cle function should also include strategies to optimize biome-
chanical advantage and use of energy conservation techniques.
If sufficient clearance of glycogen occurs with ERT, a more
complete capacity for exercise may emerge. There is evidence
in the Pompe mouse model that ERT may differentially clear
glycogen from cardiac and type Imuscle fibersmore efficiently
and more fully than from type II fibers,79 and this finding may
have an impact on strengthening.
Exercise should be performedwith appropriatemonitoring,
with rests established as needed. Facilitation of functional
movementwith graded assistancemay allow practice of appro-
priate developmental skills and strengthening within physio-
logical limits in infants. For individuals with greater strength,
gentle aerobic and submaximal functional exercise is generally
considered beneficial.
Prevention of contracture and deformity
Principles for treatment of contracture and deformity in
neuromuscular disorders are well established80 and should be
followed for individuals with Pompe disease. Contracture and
deformity should be prevented by counteracting deforming
forces with the use of gentle forces over time including daily
stretching, correction of positioning, use of splinting and or-
thotic intervention, provision of adequate support in all posi-
tions, especially sitting and supported standing as appropriate,
and education of patients and families.80 Adaptive equipment
and orthoses can be essential in the control of contracture and
deformity and can provide changes in position and pressure
relief for maintenance of skin integrity in individuals who can-
not shift their own weight or change positions independently.
Orthotic intervention often includes the use of ankle foot or-
thoses (AFO’s) to prevent plantar flexion contractures,81 thigh
binders to prevent iliotibial band contractures, knee splints to
prevent knee flexion contractures, and resting wrist/hand/
finger splints to prevent hypoextensibility in long wrist/finger
flexors over multiple joints and flexor contracture at the
wrist or in individual finger joints. Seating systems in
adapted strollers or wheelchairs are critical to prevent or
minimize contracture and deformity, especially spinal de-
formity, and should include a solid seat and back, hip
guides, lateral trunk supports, knee adductors, and head
support as needed, and as individually assessed. Supported
standing is considered beneficial to prevent or minimize
lower extremity contracture and osteoporosis82 and may in-
clude the use of supine, prone, vertical and hydraulic stand-
ers or the use of power standing capabilities on motorized
wheelchairs. Power tilt, recline and elevating leg rests on
motorized wheelchairs can allow independent position
change and weight shift for assistance in minimizing con-
tracture and maintaining skin integrity. Orthopedic surgery
may need to be considered in some cases (such as scoliosis
management), in which progression occurs beyond that
which is amenable to conservative management. Anesthesia
precautions should be followed during orthopedic surgery.
The use of positioning, splinting, and standing devices
should be coordinatedwithmedical specialists due to potential
contraindications such as cardiac or pulmonary compromise,
osteoporosis, the risk of fracture, hip subluxation or disloca-
tion, and prohibitive contractures. Consideration must be
given to the number of hours per day that a muscle is in a
shortened position, as this will determine the risk for the de-
velopment of contracture and deformity and guide successful
prevention.83
Osteopenia monitoring and management
Emerging reports of osteopenia, osteoporosis, and fracture,
suggest that screening patientswith Pompedisease for osteopenia
Kishnani et al.
278 Genetics IN Medicine
is indicated. Screening should include aDEXA (dual energy x-ray
absorptiometry). Care in interpreting the results of DEXA in in-
fants and children, is needed to ensure that the results are com-
pared with age- and gender–matched controls. At the current
time there is insufficient evidence to suggest the (z scores) fre-
quency at whichDEXA scans should be obtained in patients with
Pompe disease. The frequency should be individualized although
DEXA should not be performed more frequently than every 6
months. Factors that have the potential to contribute to osteope-
nia and osteoporosis have therapeutic implications. Nutrition
needs to be adequate especially in terms of intake of calcium and
VitaminDandattention given tomedications (e.g., long termuse
of certain diuretics which could cause hypercalciuria, long term
steroid use). Potential interventionsmay include the provision of
weightbearing in physical therapy and in standing devices.71,72
There is insufficient evidence to suggest pharmacologic therapy
such as bisphosphonates as a preventive treatment in Pompe dis-
ease at the current time. However, it may be reasonable to con-
sider introducing these agents in children having Pompe disease
and osteoporosis once the pathophysiology is better understood
and more of these medications have been proven to be safe and
effective in children with other causes of osteoporosis.
Oral motor and respiratory management related to communication
Intervention may be needed for the development of speech,
language, andcommunication in infants, childrenandadultswith
oral motor and respiratory involvement who are too weak to
readily initiate, practice, andusevocal soundproduction for com-
munication, tomaximize speechandcommunication for individ-
uals who are on ventilators or have tracheostomies, and for those
demonstrating speech delay. Positioning and support to maxi-
mize functional use of the respiratory system for sound produc-
tion should be done. Augmentative communication, including
signing and the use of assistive technology, such as voice output
systems,maybeneeded for function, to compensate forweakness
and decreased endurance, and to allow conservation of energy.
Availability and use of computers (including voice activated sys-
tems) and internet access can facilitate communication.
Function
At every age and stage, appropriate function and maximal
levels of independence, governed by medical stability, should
be encouraged. Functional developmental activities and inde-
pendence in the activities of daily living should be supported.
Family education is essential in fostering appropriate indepen-
dence. The use ofmobility devices such as canes, walkers,man-
ual wheelchairs, and poweredmobility are usually added grad-
ually in late onset disease, often used part-time at first, for long
distance communitymobility or on uneven terrain.Motorized
mobility should be considered early in infantile onset Pompe
disease, at developmentally appropriate ages.84 Adapted car
seats can be used for infants and children, and those designed
for infants with poor head control should be used for safe
transport of fragile infants. Appropriate assistive technology
should be provided with training in its use at home and in
educational and work tasks in order to maximize function,
functional independence, safety, access and participation.
Driving may be appropriate, depending on age and abilities.
Provision of service
Rehabilitation services may be provided in the home, in
center-based programs, at school, in inpatient facilities, and
in outpatient settings, depending on the needs and prefer-
ences of the individual and the family. Services, adaptive
equipment, and assistive technology may be funded by nu-
merous different agencies, as outlined below under care co-
ordination.
MUSCULOSKELETAL/FUNCTIONAL/REHABILITATION
RECOMMENDATIONS
● Monitor cardiorespiratory status and response to posi-
tion and activity with pulse oximetry during evaluation
and treatment initially and with changes in status or ac-
tivity.
● Screen for osteopenia/osteoporosis with DEXA and fol-
low-up as needed.
● Assess musculoskeletal impairments, functional deficits,
levels of disability, and societal participation at regular
intervals and as needed, including radiographs as needed
for monitoring of scoliosis, hip stability, and long bone
integrity.
● Enhance Muscle Function:
 increase biomechanical advantage for movement:
 provide practice, movement, and gentle strength-
ening within limits of physiological stability.
 provide rests as needed to avoid overexertion.
 follow guidelines for strengthening from other
progressive muscle diseases:
y submaximal, functional, and aerobic exercise rec-
ommended.
y avoid excessive resistive and eccentric exercise.
y avoid overwork weakness.
y avoid disuse atrophy.
 allow compensatorymovements necessary for func-
tion, but prevent negative results (contracture and
deformity).
● Prevent/Minimize/Correct 2° Musculoskeletal
Impairment (Contracture/Deformity):
 stretching/positioning.
 orthotic intervention and splinting.
 seating systems/standers.
● Optimize function with adaptation and assistive tech-
nology as needed.
● Educate the patient and family about the natural history
and recommendations for intervention.
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NEUROLOGICAL
Central nervous system
The natural history of Pompe disease largely reflects the
pathologic consequences of glycogen accumulation in skeletal
and cardiac muscle, but autopsy studies have also demon-
strated glycogen accumulation in the brain, brainstem nuclei
and anterior horn cells.2 Cognitive function is usually thought
to be normal in both infantile and late onset disease, but it is
possible that subtle impairmentsmight become apparent if the
natural history of infantile Pompe disease is preferentially
modified by emerging therapies such as ERT.
Anterior horn cell involvement is manifest as EMG signs of
denervation in these children.2 Clearance of muscle glycogen
by ERT leading to improved skeletal muscle function and pro-
longed survival might theoretically lead to the emergence of
late onset Pompe/spinal muscular atrophy phenotypes in such
cases and a long-term follow up of these patients is needed.
Affected individuals should be followed using appropriate
standardized instruments as described above. Motor unit
number evaluation (MUNE) has shown promise in studies of
SMA, and should be considered as an adjunctive assessment of
anterior horn cell function in future studies of patients receiv-
ing ERT. (see appendix 1 for discussion of quantitative muscle
testing, electromyography, histopathology, use of the Pompe
Pediatric Evaluation of Disability Inventory (PEDI), and func-
tional motor testing (timed tests, arm and leg functional test-
ing)).
Hearing loss has been recognized in some infantile Pompe
disease patients, and may reflect direct involvement of the co-
chlea (rare), the conductive apparatus (common), or both.85
In a series of 20 patients with infantile Pompe disease seen at
Duke University, nearly 80% of the ears tested demonstrated
Distortion Product Otoacoustic Emissions (DPOAE) sugges-
tive of normal or near normal cochlear function. 73% of the
ears tested had abnormal tympanometry consistent with mid-
dle ear dysfunction. None of the patients in this series had
absent DPOAE’s in the presence of normal tympanometry,
decreasing the likelihood of cochlear involvement (personal
communication, Priya Kishnani, MD, and Gwen O’Grady,
MA, 2006). In addition to standard neonatal hearing screen-
ing, children should have baseline, routine, and annual hearing
tests. Testing should include behavioral assessment when pos-
sible, otoacoustic emissions, tympanometry, and Auditory
Evoked Potentials (ABR/BAER) using air and bone conducted
stimuli. Individual rather than normative data should be used
to determine site of lesion of the hearing loss due to the ex-
treme variability seen in the normative data available in the
pediatric (18 months) population and the maturational ef-
fects observed in evoked potential testing.86 Careful interpre-
tation of tests by audiologists with pediatric experience is nec-
essary as children with infantile Pompe disease are difficult to
accurately assess due to their motor and other delays as well as
the increased incidence of middle ear involvement. As with all
pediatric patients, clinical circumstances such as frequent epi-
sodes of otitis media (OM) may dictate more frequent exami-
nations. Aggressivemedical therapy of OM and chronic serous
OM should be pursued, with surgical intervention reserved for
treatment failures (note: see cautions in “Surgery andAnesthe-
sia”). Hearing re-evaluation should be performed following
medical/surgical intervention to ensure remediation of any po-
tential conductive component. Hearing aids should be used
when indicated because permanent hearing loss has been iden-
tified.
Some patients with Pompe disease experience fever of un-
certain origin, presumed to be of central origin. As outlined in
“GeneralMedical Care” all patients should be thoroughly eval-
uated for sources of infection and considered for empiric treat-
ment until a negative workup for infectious and inflammatory
disorders is completed. There are also reports of glycogen ac-
cumulation in vascular smoothmuscle resulting in aneurysms/
rupture of blood vessels such as the basilar artery87,88 internal
carotid artery andmedial cerebral arteries in patients with late-
onset Pompe disease.89,90 This has resulted in focal weakness
and in the extreme instance even death. Vascular involvement
of intracranial blood vessels should be considered in the work
up and evaluation of patients with Pompe disease, especially
those that are symptomatic.
NEUROLOGY RECOMMENDATIONS
● Motor and functional assessments are recommended to
establish a baseline with repeat testing at 3–6 month
intervals for children under age five years, and annually
in older children and adults, except where additional
testing is clinically indicated by change in function or
failure to make expected progress.
● Perform needle electromyography (EMG) in initial
evaluation to determine presence of denervation as evi-
dence of anterior horn cell involvement.
● Perform nerve conduction studies at initial evaluation.
● Perform hearing tests including behavioral assessment
otoacoustic emissions, tympanometry and auditory
evoked potentials (ABR/BAER) using air and bone
conducted stimuli to establish baseline and repeat age
and condition appropriate hearing testing, annually,
as clinically indicated and following medical/surgical
intervention.
GENERAL MEDICAL CARE
Due to the overall hypotonia, cardiomyopathy (in infantile
presentation) and respiratory muscle weakness, individuals
with Pompe disease are at very high risk for pneumonia and
other infections which may lead to respiratory failure, intuba-
tion with ventilator dependence and even death. Infections
need to be managed very aggressively in this population and
the threshold to treat infections should be low. Immunizations
should be kept up to date and patients and household mem-
bers should receive the influenza vaccine during influenza sea-
son. Furthermore, palivizumab (Synagis) should be used dur-
ing respiratory syncytial virus (RSV) season, in infants and
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‘young children with Pompe disease as this can be life-threat-
ening in these patients. Pneumococcal vaccine (Prevnar) is
currently part of the routine immunization schedule, however
the 23 valent peumococcal vaccine should be administered af-
ter 2 years of age and for older patientswhohave not previously
received it. Strict hand washing precautions should be imple-
mented to avoid infections. Medical attention should be
sought for common symptoms such as a cough or fever as it
may indicate a more serious underlying condition. Another
important consideration is careful use of over the counter
medications to treat colds, cough and other URI symptoms as
they often contain sympathomimetic agents which can be det-
rimental to the heart. The risk benefit ratio of use of medica-
tions such as steroids (risk of progressive muscle weakness and
osteopenia) and loop diuretics (ototoxicity and calciuria)must
be considered prior to administration.
Similarly, infectious agent precautions and aggressive man-
agement of infections should be the rule in late-onset patients.
GENERAL MEDICAL CARE RECOMMENDATIONS
● There should be strict hand washing and aggressive
management of infections.
● Routine immunizations, including pneumococcal vac-
cination, should be used.
● There should be influenza vaccination for patients and
other household contacts and use of palivizumab when
indicated.
● There should be careful use of over-the-counter medi-
cations and concomitant medications.
SURGERY/ANESTHESIA
Providing safe anesthesia for infants with Pompe disease
is a challenge due to the severe hypertrophic cardiomyopa-
thy and the resultant hemodynamic alterations. Myocardial
ischemia and decreased cardiac output are not uncommon
events during anesthetic management in infantile Pompe
disease. The thickened ventricular wall results in a higher
left ventricular end-diastolic pressure (LVEDP) at lower
ventricular volumes and an increased potential for suben-
docardial ischemia. Maintaining a normal coronary perfu-
sion pressure is thus of paramount importance.26 Intraop-
erative cardiac arrest during halothane anesthesia and
sevoflurane inhalation induction followed by a mainte-
nance infusion of propofol in infantile Pompe has previ-
ously been reported.91,92 With the advent of emerging ther-
apies such as ERT, survival of these patients has increased
and more surgical procedures are being performed. The pa-
tients need intensive monitoring and thus surgical proce-
dures should be done with extreme caution and conducted
at sites with experienced pediatric/cardiac anesthesiologists.
Avoidance of intubation is generally preferred but may be
unavoidable in certain circumstances (e.g., macroglossia).
When multiple procedures are needed, they may be done as
a group, when appropriate, under a single anesthesia. Care-
ful attention to peri-operative fluids is necessary as the dy-
namic left ventricular outflow tract (LVOT) obstruction can
be exacerbated in the presence of hypovolemia. However,
overly aggressive fluid resuscitation may lead to pulmonary
edema in patients with elevated LVEDP. Echo-derived indi-
ces of 2DLVmass and ventricular cavity volume, in addition
to EF, should be used as parameters of myocardial function
in planning an anesthetic, as EF alone may be misleading in
this patient population. Five lead ECG with continuous ST
segment monitoring and placement of an indwelling arte-
rial catheter should be strongly considered, if cardiac dis-
ease is advanced. The goals of anesthesia are to maintain a
higher filling pressure for adequate preload and a normal to
high systemic vascular resistance to ensure effective coro-
nary perfusion. Anesthetic agents should thus be chosen to
address the marked myocardial hypertrophy and its physi-
ological effects on preload and afterload. Ketamine main-
tains systemic vascular resistance (SVR) and contractility
and is less likely to reduce preload. It is an example of an
agent which offers a safer profile in this patient
population.92 Etomidate is another acceptable induction
agent.93 Inhalational agents and thiopental, should be used
with caution and be reserved for patients with less myocar-
dial hypertrophy. Propofol, particularly in higher doses ad-
ministered to achieve general anesthesia, rather than seda-
tion, may not be the ideal anesthetic agent for Pompe
patients, since afterload reduction and a lower diastolic
pressure may predispose these infants to the risk of myocar-
dial ischemia. Deaths have been reported (unpublished
data) with propofol as the anesthetic agent. Because of the
underlying muscle weakness Pompe patients may be more
sensitive to neuromuscular blockade. Agents such as suxa-
methonium should be avoided in Pompe disease as in all
myopathic patients due to the potential risk of rhabdomy-
olysis and hyperkalemia. Malignant hyperthermia precau-
tions should be taken. After recovery from anesthesia in-
fants may be managed on the ward or in an intensive care
unit depending on clinical status.
SURGERY/ANESTHESIA RECOMMENDATIONS
● Anesthetic procedure only when absolutely necessary.
● Consolidation of procedures requiring anesthesia, to re-
duce risk of repeated anesthetic exposures.
● Judicious use of anesthetics, with precautions followed
due to underlying cardiomyopathy.
● Procedures at centers with experience anesthetizing pa-
tients with Pompe disease or consulting with experts.
● Avoidance of intubation, if possible.
CARE COORDINATION AND NURSING
Care coordination of individuals with Pompe disease is es-
sential to the support and treatment of the patients and their
families andmay be dictated by the patient’s local demograph-
ics and individual needs. Local customs, insurance require-
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ments and other factors contribute to decisions of who as-
sumes this role. Nurses, genetic counselors, local primary care
providers, medical geneticists andmetabolic disease specialists
and neurologistsmay take a central role in providing culturally
sensitive care.94,95 Social workers may also facilitate and coor-
dinate some of the services. Individuals assuming the various
roles should have current knowledge of the disease process as
discussed in previous sections, as well as a comprehensive un-
derstanding of the patient’s needs in the therapeutic settings
and the community. Education of team members is often re-
quired to teach the family and other resource personnel about
the disease process and needed medical procedures, and the
anticipated future needs and cautions for optimum care of the
patient.
Recognizing that the “family” is the constant in a patient’s
life, the plan of care should be centered on needs identified by
the family and medical/therapeutic providers working as a
team. Parent/family/patient collaboration with the profes-
sional team should be facilitated at all levels of care to allow for
equal participation in establishing the goals of care. Multiple
needs which may include separation from core family mem-
bers due to hospitalization or therapy, transportation, lodging
costs, loss of work days, specialized equipment including an
adapted vehicle, household assistance, regular medical proce-
dures, vocational retraining, and educational programming
should be addressed. Information about therapies, treatments,
and resources should be continuously sharedwith the family in
an appropriate and supportivemanner that is sensitive to fam-
ily relationships and respectful of the patient’s position in the
family. Timely referrals to appropriate community agencies,
including a social worker or other case worker, and advocating
for the needed community services is essential support that can
be facilitated by the individual coordinating the care of the
patient.
The coordinator, in consultation with the physician provid-
ing care should recognize the specialized medical and thera-
peutic care that is required by the patient and should be able to
triage and refer them to specific providers as needed. The
strengths, preferences, and coping mechanisms of the patient
and family should be respected and incorporated into the
needs assessment. In addition, any cultural, religious, language
or racial differences and sensitivities should be recognized in
the development of the plan of care.
Parent to parent and patient to patient support has been
reported by many to be one of the most valued resources pro-
vided. Resources for this support are outlined in the following
section. Another consideration is to identify support for sib-
lings, grandparents and other family members.
The care coordinator should insure that the patient/family is
aware of the medical support that has been coordinated, pro-
vide the family with the appropriate contact information, and
with the patient/ family permission, facilitate appropriate in-
formation sharing. The family and all providers should be up-
dated on the care plan and patient progress at regular intervals.
This will insure comprehensive coordinated care that is family
centered.
Family needs and resources
The added responsibilities of living with Pompe disease ex-
tend beyond the patient often to a vast network of family and
friends. Pompe patients want not simply to live, but to thrive-
and many of them do just that. To achieve this, there are con-
stant strains and challenges which takemany forms - financial,
educational, emotional and psychological. There is today a vast
network of resources and information, both public and pri-
vate, that can ease the burdens of this disease and add greatly to
the Pompe patient’s quality of life.
The Muscular Dystrophy Association
The Muscular Dystrophy Association (MDA) is a not-for-
profit organization whose goal is to fight neuromuscular dis-
eases through a nationwide research effort, a program of
patient medical services and extended education for pro-
fessionals and families. Pompe disease is one of about 40 neu-
romuscular diseases included within the scope of the MDA’s
mission and services. The MDA maintains 235 hospital-affili-
ated clinics with nurses, physicians and therapists experienced
in neuromuscular diseases. Pompe patients may access all of
these services.
In addition, for children, the MDA offers special programs
that directly offset the cost of medical equipment, including
wheelchairs and other mobility assistive devices. The MDA
also sponsors over 90 summer camps which are free of cost
across the United States for children with neuromuscular dis-
ease. These camps offer children with all diseases, including
Pompe, the chance to playwith other special needs kids in a fun
and safe environment.
The MDA also has extensive knowledge and resources re-
lated to the challenges of families living with neuromuscular
diseases, including Duchenne muscular dystrophy, Pompe
disease and spinal muscular atrophy (SMA). Pompe families
will find of particular benefit a book published by MDA enti-
tled “Learning to Live with Neuromuscular Disease—a message
for parents.”96; This book, published first in 1998, addresses
such topics as: taking on the challenge; facing your feelings; the
importance of reaching out; strength in family relations; and,
what your child needs. The book can be found on the MDA
web site (see below).
Indeed, the challenges that most Pompe patients and their
families face are enormous. They often times strain relation-
ships, friendships and marriages – sometimes they even break
them. This stress is a natural part of the shared burdens that
surround the care of a person with Pompe. Those families that
deal best with these life-altering challenges are enriched by the
understanding andmutual concern that becomes a compelling
and dominant force in their lives.
The MDA web site contains useful information. See www.
mdausa.org/publications/learning/ or the MDA can be con-
tacted by telephone at 1-800-572-1717 (US) or 520-529-2000
(international).
Other agencies and web sites specific to related diagnoses
such as DMD and SMA can provide additional information
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including: Parent Project Muscular Dystrophy (http://www.
parentprojectmd.org), Families of SMA (http://www.fsma.org),
and the SMA foundation (www.smafoundation.org).
Medicaid
Medicaid is a joint state-federal entitlement program which
provides primarilymedical care to low-incomeAmericans.Med-
icaid has evolved over time andnowoffersmany benefits for pro-
viding home and community services to patients with long-term
care needs, such as many of those living with Pompe. Medicaid
gives each state broad discretion to cover virtually all long-term
care services that people with disabilities need to live indepen-
dently in both home and community settings.
Eligibility forMedicaid varies by state but in every case it is a
means-tested entitlement program. For those who qualify, it
provides ameans for access to a wide range ofmedical services.
For children with Pompe requiring home nursing and who
do not otherwise qualify for Medicaid, other funds may be
available. The “Katie Beckett” (or “TERFA”) option is a Med-
icaid waiver program (http://www.cms.hhs.gov/medicaid/
waivers/) that enables states to provide Medicaid specifically
for home health care expenses for disabled children and may
also cover therapy services, adapted equipment, aide services,
and respite care. This is an optional program for each state.
Since each state sets its own rules for coverage, please visit
www.cms.hhs.gov/medicaid to review each individual state’s
scope of coverage and programs. Early Intervention Services
are supported by the Early Infant Program for Infants and
Toddlers with Disabilities, Part C of the federal Individuals
with Disabilities Act (IDEA) which coordinate and fund ser-
vices for children from birth to 3 years of age (http://www.cec.
sped.org/law_res/doc/law/regulations/indexPartC.php). Other
federal legislation such as the Public Law 94-142 and the Re-
habilitation Act, including Section 504, insure a free public
education in the least restrictive environment possible, includ-
ing the provision of therapy services (PT, OT, ST) when edu-
cationally relevant, and assuring access (http://www.ed.gov/
policy/speced/leg/edpicks.jhtml?src ln).
Other valuable government sources of information include
the National Information Center for Children and Youth with
Disabilities (NICHCY) and the Council for Exceptional Chil-
dren. NICHCY is a national information and referral resource
for families with disability-related issues (www.nichcy.org).
The Council for Exceptional Children (www.cec.sped.org) is
an international professional organization dedicated to im-
proving educational outcomes for individuals with exception-
alities. Also of value to Pompe families, particularly adult
Pompe patients, may be the website www.disabilityinfo.gov.
This website offers a significant collection of resources includ-
ing information on housing, employment, education, income
support, technology, and community support.
Other private not-for-profit organizations that provide ad-
ditional potential sources of support and funding for Pompe
patients include The Disabled Children’s Relief Fund (www.
dcrf.com). The DCRF focuses on helping children who do not
have adequate health insurance, especially the physically chal-
lenged. It provides disabled children throughout the United
States with assistive devices, rehabilitative services, and sup-
port for arts and humanities projects.
Pompe patient organizations
The International Pompe Association (IPA) is a federation
of Pompe disease patient groups worldwide. It seeks to coor-
dinate activities and to share experience and knowledge be-
tween different groups. Membership in the IPA is open to
Pompe and related disease groups. As such, the IPA acts as an
umbrella organization for patient organizations globally. One
of themost valuable forums for Pompe patients annually is the
IPA patient conference held in the Fall of each year.
In the United States, there are two primary Pompe patient
support groups: the Acid Maltase Deficiency Association
(AMDA) and theUnited Pompe Foundation. Both groups aim
to broaden public awareness and knowledge of Pompe as well
as to support select research initiatives at Universities. (www.
amda-pompe.org and www.unitedpompe.org).
GENETIC COUNSELING, PRENATAL
DIAGNOSIS AND SCREENING
Genetic counseling and prenatal diagnosis
Genetic counseling should be offered to all parents with
an affected child with Pompe disease and to all adults with
Pompe disease. In counseling families with Pompe disease,
at least a three generation pedigree from the consultand or
proband should be obtained. Pompe disease is an autosomal
recessive condition. De novo mutation rates are expected to
be low and parents of an affected individual are assumed to
be carriers. The recurrence risk to parents who have had an
affected child is 25%. DNA mutation analysis is necessary
for the identification of additional family members in the
extended family who may be carriers. A small number of
laboratories offer DNA diagnostic and/or prenatal diagnos-
tic testing for Pompe disease (see www.genetests.org and
http://biochemgen.ucsd.edu/). Some genotype:phenotype
correlations have been observed.2,97 Some laboratories may only
screen for common mutations rather than provide full gene
sequencing. Identification of carrier status in the general pop-
ulation (e.g., in the spouse of a known carrier) is limited and
currently not routinely offered. Such individuals can be tested
for the commonmutations to further refine their risk for hav-
ing a child with Pompe disease.
Prenatal diagnostic testing is typically performed by mea-
suring enzyme activity in uncultured chorionic villus sam-
ples.98,99 Enzyme analysis in amniocytes has also been success-
fully performed but enzyme activity is typically lower than in
chronionic villus studies. Prenatal diagnostic testing by muta-
tion analysis is feasible, it allows for confirmation of the bio-
chemical assay and the absence of contamination of chorionic
villus samples, and offers advantages over biochemical meth-
ods, if the proband’s mutation has been identified. Therefore,
identification of the proband’s GAA mutations, if a sample is
available for testing, should be a priority. In equivocal cases, a
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combination of methods can be used, and some laboratories
prefer to offer prenatal enzyme analysis with results confirmed
byDNAmutation analysis.When themutations segregating in
the family are known,molecular testing is the gold standard.100
Preimplantation genetic diagnosis (PGD) is also potentially an
option for Pompe disease families if specific mutations have
been identified.
Screening
The development of Chinese hamster ovary (CHO) cell-
derived recombinant human acid alpha glucosidase (rh-
GAA) enzyme replacement therapy that is currently in clinical
trials shows promise. Results from several different trials with
CHO enzyme and also transgenic enzyme from rabbit milk in
earlier trials have shown that patients treated early in the dis-
ease, prior to the development of extensive tissue damage, are
likely to have the best outcome.101–105 A clinical trial of 18
patients with classic infantile Pompe disease treated with CHO
cell derived rhGAA at age  6 months was recently
completed.106 At the end of 1 year of therapy all patients were
alive and 83% were alive and free of invasive ventilation. Data
from this and other trials were submitted to the Food andDrug
Administration for a Biologics License Application in July,
2005. The results from this study build on previous experience
and underscore the need for early recognition of affected pa-
tients to allow for timely intervention and the best chance for a
good outcome. The recent expansion of newborn screening in
theUnitedStateshas led to the early, presymptomaticdiagnosisof
over30different inbornerrorsofmetabolism.The firstpilot study
of newborn screening for lysosomal storage disorders (Krabbe
disease) has begun in New York (though Pompe disease is not in
the initial group being tested) and in Taiwan (Pompe disease is
included).
Methods for high throughput screening of GAA activity,
using the newborn screening dried blood filter specimen
(DBS), have been developed and are being validated in large
population screening programs.29-31,107 If successful, newborn
screening for Pompe disease can become a reality.
GENETIC COUNSELING/PRENATAL DIAGNOSIS/
SCREENING RECOMMENDATIONS
● Offer genetic counseling to all parents with an affected
child with Pompe disease and to all adults with Pompe
disease.
● Determine the proband’s GAAmutations when feasible.
For prenatal diagnosis,
● molecular testing is the preferred method when both
mutations are known;
● enzyme analysis in chorionic villus samples is pre-
ferred whenmolecular testing is not feasible, or when
enzyme analysis is an adjunct to molecular testing,
though confirmation in amniocytes may be consid-
ered if mutations are known.
ENZYME REPLACEMENT AND OTHER EMERGING
THERAPIES
Several open-label clinical trials involving patients with in-
fantile-onset Pompe disease have shown that enzyme replace-
ment therapy significantly prolongs survival,102–110 decreases
cardiomegaly, and improves cardiac and skeletal muscle func-
tion. In the vast majority of cases cardiac response appears to
be good, irrespective of the stage of the disease at the start of
ERT. Skeletal muscle response has been more variable than
cardiacmuscle response. The best skeletal muscle response has
been noted in patients treated early, prior to severe skeletal
muscle damage. There are several patients with infantile-onset
Pompe disease on ERT who are walking, a milestone that
would not have been achieved without ERT. Thus with the
advent of ERT, the natural history of this once lethal disease
has changed and additional physical and mental disabilities
may be uncovered. However, there are patients who have not
had a good outcome despite early treatment. Factors such as
muscle fiber type, stage of disease at start of therapy, genotype
and immune response to the recombinant enzyme may play a
role in determining outcome and need further investigation.
Additional larger-scale trials in infants to establish the extent of
long-term benefit, the optimal dosing protocol, and the effect
of other factors on outcome of therapy are needed and are
currently underway. Trials of ERT in late onset Pompe disease
are also underway. With the introduction of therapies such as
ERT, long term survival is now a reality and closer attention to
the natural history of treated patients is of paramount impor-
tance. However, the possibility that neurological manifesta-
tions may be uncovered during long-term ERT for infantile
onset Pompe disease remains to be resolved.
Progress continues to be made in the development of gene
therapy for Pompe disease. Several proof-of-concept studies in
Pompe mice demonstrate that various gene delivery vector sys-
tems including retrovirus,111 adenovirus112–115 andmost recently
recombinant adeno-associated viral (AAV) vectors116–121 have
potential. Studies demonstrate that expression of the acid alpha
glucosidase gene withinmuscle cells or in some cases secretion of
GAA from liver leads to a reduction of the glycogen storage ab-
normality in the mice. Moreover, these studies showed that the
immune response to the expressed enzyme in AAV-treated
Pompe mice treated can be reduced in some cases117,121 or be
influenced by tissue specific expression.118,119
The use of small molecules to treat lysosomal storage disor-
ders is also emerging as a therapeutic option either as a single
agent or in combination with other therapies. Work on a sec-
ond generation recombinant enzyme for Pompe disease for
more efficient targeting tomuscle is currently in the preclinical
stages. Pharmacologic chaperones that bind to the affected
proteins and restore their shape, proper trafficking, and bio-
logical activity may also become available for those who can
make protein. Several challenges remain before clinical testing
of these therapeutic strategies can be considered. In the case of
gene therapy, work still remains, especially in terms of safety.
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At the current time with the advent of enzyme replacement
therapy and the likelihood of its availability in the near future
early recognition and appropriate medical management of
Pompe disease has assumed new importance. Thus, physicians
need to be alert to the signs and symptoms of this disease to
facilitate early pick up and allow for therapeutic interventions
as they become available. A multidisciplinary team approach
should be followed to ensure the best care and outcome for
these patients.
In order to optimize recommended disease support mea-
sures, a mechanism to collect longitudinal patient data as a
means to follow the general disease population and assess the
impact of disease support measures as used by physicians
around the world is needed. The gold standard for such studies
may be the U.S. National Cancer Cooperative Groups that al-
lowed for participation of 85–90% of all children with leuke-
mia and cancer in the U.S. in protocol driven studies with peer
reviewed laboratory and clinical data from entry into the stud-
ies through outcome. This system was particularly important
in providing the statistical power necessary for informing stud-
ies and clinical trials for rare diseases. In the absence of such
study systems, registries can be useful. The PompeRegistrywas
launched in September 2004 as a global, observational data-
base to track de-identified natural history and outcomes data
for monitoring and analysis by the global Pompe disease med-
ical community. Registry participation is open to all physicians
managing patients with a confirmed diagnosis of Pompe dis-
ease. The Pompe Registry will act as a repository for disease
natural history and select clinical trial data and as a platform to
gather prospective data on current and future Pompe patients
for a number of years. Information on the registry can be found
at www.pomperegistry.com.
APPENDIX A – MOTOR AND FUNCTIONAL
ASSESSMENTS
Motor and functional assessments are recommended to es-
tablish a baselinewith repeat testing at 3 – 6month intervals for
children under age five years, and annually in older children
and adults, except where additional testing is clinically indi-
cated by change in function or failure to make expected
progress. The following list includes most of the major assess-
ments but is not intended to be an exhaustive listing of all
possible assessments or tools used in assessments.
Musculoskeletal
● passive ranges of motion and measures of muscle exten-
sibility (goniometry)
● posture and alignment in all positions
● spine:
 flexibility, stability, posture and alignment
 monitoring for kyphosis, scoliosis, lordosis
● hip joint stability/integrity
● DEXA
● radiographs as needed formonitoring hip and spine status
Qualitative/kinematic assessment of compensatory move-
ment /strategies formovement
Strength - “pure” measures of muscle strength (specific
tests chosen based on age and level of strength)
● manual muscle testing (MMT)
● quantitative muscle testing
 dynamometry – different types and brands
▫ isometric hand held or fixed – norms exist from4
to 79 years of age122,123
▫ grip - norms exist from ages 6 years to 79
years124,125
▫ pinch - norms exist from ages 6 years to 79
years124,125
 other quantitative measures (isokinetic, isotonic,
isometric)
Functional Measures (including functional measures of
strength):
(specific tests chosen based on age and purpose of func-
tional exam)
● Alberta Infant Motor Scales126
● Gross Motor Function Measure (GMFM)127
● Timed Functional Tests128
● Six Minute Walk129
● Functional Grades130
● Peabody Developmental Motor Scales 2131
Measures of Disability: (measures chosen may depend on
age, setting, context)
● Pediatric Evaluation of Disability Index (PEDI)132
● Pompe PEDI133
● Functional Independence Measure (FIM)134
● WeeFIM135
Pain Scales: (scales used depend on age, level of function)
● CRIES Pain Scale136
● FACES Pain Scale137–139
● Pediatric Objective Pain Scale
● Visual Analogue Scales (VAS)
Health Related Quality of Life (HRQOL)Measures
● Short Form 36 (SF36) Health Survey140
● Sickness Impact Profile141
● Center for Disease Control HRQOL (www.cdc.gov/
hrqol/hrqol14_measure.htm)
● PedsQL142
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